



**Patients Enrolled
(N=156)**

**Placebo Group
(N=52)**

**Olanzapine Group
(N=104)**

Discontinued (n=11)

n

Adverse Event	4
Clinical Relapse	0
Entry Criteria Not Met	0
Lack of Efficacy	1
Lost to Follow Up	0
Physician Decision	0
Protocol Violation	1
Subject Decision	5

Discontinued (n=18)

n

Adverse Event	10
Clinical Relapse	0
Entry Criteria Not Met	0
Lack of Efficacy	0
Lost to Follow Up	1
Physician Decision	0
Protocol Violation	0
Subject Decision	7

**Completed
Study
(n=41)**

**Completed
Study
(n=86)**